Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis
Journal of the Neurological Sciences. May 15 2018;388:168-174
To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate.
A systematic literature review was conducted (MEDLINE, EMBASE, and abstracts from selected conferences [2013-2015]) to identify observational studies reporting 1-year fingolimod persistence among adult patients with RRMS (sample size ≥50). A random-effects meta-analysis was performed to estimate a synthesized 1-year persistence rate and to assess heterogeneity across studies.
Of 527 publications identified, 25 real-world studies reporting 1-year fingolimod persistence rates were included. The studies included patients from different data sources (e.g., administrative claims, electronic medical records, or registries), used different definitions of persistence (e.g., based on prescriptions refills, patient report, or prescription orders), and spanned multiple geographic regions. Reported 1-year persistence rates ranged from 72%-100%, and exhibited statistical evidence of heterogeneity (I2 = 93% of the variability due to heterogeneity across studies). The consensus estimate of the 1-year persistence rate was 82% (95% confidence interval: 79%-85%).
Across heterogeneous study designs and patient populations found in real-world studies, the consensus 1-year fingolimodpersistence rate exceeded 80%, consistent with persistence rates identified in the recently-completed trial, PREFERMS.
Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V